Avidin and its partners Steinbeis-Innovationszentrum Zellkulturtechnik (SIZ) and GenXPro awarded with EUREKA Innovation award as part of a special German-Hungarian collaborative program

03/01/2019. Project title: Functional genomic and enzymatic profiling of mitochondria from oxidative stressed biological samples Identification number of the project: 2018-2.1.3-EUREKA-2018-00016 Cost of project: 95 411 001 Ft Funding amount: 66 787 700 Ft Funding rate: 70% Expected duration of the project : 01.02.2019-12.31.2020. In the last decade, oxidative stress has emerged as a key factor in many diseases including ...

AVIDIN’s CEO László Puskás was recently awarded

AVIDIN’s CEO László Puskás was recently awarded with the Dénes Gábor Prize of the NOVOFER Foundation in the Hungarian Parliament for AVIDIN’s lead project, the compound which can make a breakthrough in Alzheimer’s Research and can make a difference in the life of millions of elderly and indirectly the societies worldwide affected by this uncurable disease.

Avidin granted with award of Competitiveness and Excellence Co-operations (VKE)

Identification number of the project: 2018-1.3.1-VKE-2018-00024 Title: Multiparametric immunophenotypic study to characterize diabetes patients Expected duration of the project: 2018.10.01- 2021.09.30. Cost of project: 833 558 791 Ft Funding amount: 647 544 171 Ft Partners of consortium: TS Lab Trade and Service Limited Liability Company, AVIDIN Ltd., HR-Pharma Ltd. and HAS Biological Research Centre Project summary: Genetic predisposition and life style management ...

Our most advanced project’s lead optimization results published

Novel 8-hydroxyquinoline pharmacophore scaffold was synthetized by Avidin’s Medicinal Pharmacolgy department which has been shown to possess a range of activities as metal chelation, enzyme inhibition, cytotoxicity and cytoprotection. Based on our previous findings we set out to optimize the scaffold for cytoprotective activity for its potential application in central nervous system related diseases. A 48-membered Betti-library was constructed by the utilization …

Avidin organized the fifth TAT-CF general assembly held in Budapest.

The famous Géllert Hotel was the venue selected for meeting. Thursday 14th was dedicated to a workshop session where all the partners presented the most recent progress in their respective work packages. Exciting results from TAT-CF selected hits raised the expectations toward a successful outcome of the project. A total of 10 presentations from the eight TAT-CF partners reviewed all …

Lewis Acid-Catalyzed Diastereoselective Synthesis of Multisubstituted N-Acylaziridine-2-carboxamides from 2H-Azirines via Joullié–Ugi Three-Component Reaction

Lewis Acid-Catalyzed Diastereoselective Synthesis of Multisubstituted N-Acylaziridine-2-carboxamides from 2H-Azirines via Joullié–Ugi Three-Component Reaction (doi: 10.1021/acs.joc.7b03189) 3-9-2018 Avidin’s Medicinal Chemistry Department developed and established an innovative protocol for a ZnCl2-catalyzed diastereoselective Joullié-Ugi three-component reaction from 2 H-azirines, isocyanides, and carboxylic acids. The protocol allows the preparation of highly and diversely functionalized N-acylaziridine-2-carboxamide derivatives in up to 82% isolated yields. Additionally, the applicability …

Our single cell protection buffer, the SingleCellProtectTM

Our single cell protection buffer, the SingleCellProtectTM  was used in a recently published Nature Communication paper (doi:10.1038/s41467-017-02628-4) 3-4-2018 Previously we showed that single cells collected for genomic analysis without our protection buffer resulted in more variations and less RNA both in RNASeq and quantitative real-time PCR methods. Our specially formulated solution the SingleCellProtectTM ensures excellent quality RNA for single cell …

Avidin joined to fourth cystic fibrosis consortium (H2020 TAT-CF) progress meeting in Mallorca (Spain)

Day one was dedicated to the 3rd TAT-CF workshop in which researchers from all partners presented their work within the H2020 project (Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters No 667079). The second day, principal investigators discussed key issues during the Steering Committee meeting. The project has entered into its last year …

Recent Press release announced Hungarian companies can make a breakthrough in combating Alzheimer’s disease

The fruitful collaboration of AVIDIN Ltd. and SONEAS Research Ltd. working in the field of drug development has produced outstanding results from professional and also business point of view. AVIDIN Ltd. has dedicated to pharmaceutical research of Alzheimer’s disease from 2009. During the company’s chemical and molecular-level biological development, a novel drug candidate Q134R-K was discovered which has been patented …

Avidin’s chemistry R&D unit divided into new Divisions

Avidin’s chemistry R&D unit responsible for chemical synthesis and development was divided into two Divisions: Medicinal Chemistry Department lead by Iván Kanizsai, PhD and Organic Chemistry Department, where Árpád Balázs, PhD was appointed as the leader. Medicinal Chemistry Department is responsible for hit discovery and lead optimization supporting different drug discovery programs. Organic Chemistry Department is responsible for chemical development, …